Five Prime Therapeutics (FPRX) Posts Q4 Loss of 55c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts FPRX Hot Sheet
Join SI Premium – FREE
Five Prime Therapeutics (NASDAQ: FPRX) reported Q4 EPS of ($0.55), $0.45 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $4.65 million versus the consensus estimate of $12.4 million.
For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Wells Fargo Names Top Pick Ahead of Q3 Earnings
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
